Peptide
KPV
KPV (Lys-Pro-Val, alpha-MSH C-terminal tripeptide)
The three C-terminal amino acids of alpha-MSH, isolated as an anti-inflammatory peptide. Preclinical evidence in colitis and dermatitis. Voted for the FDA 503A compounding list by the PCAC advisory panel in July 2026.
Summary Can KPV reduce inflammation, and is it ready to use? Show / hide ↓
KPV is a tiny piece of a natural hormone that may help calm inflammation without causing the hormone’s effects on skin color or appetite. Studies in mice with bowel inflammation and in skin inflammation models showed improvements, but animal results do not prove it works in people. A few small, open-label human studies in ulcerative colitis and inflammatory bowel disease found modest improvements, but there were no large trials with a comparison group. In July 2026, a US FDA advisory panel voted 12 to 1 to recommend KPV for a list that could allow prescription compounding, but the vote is not final and FDA scientists raised safety concerns. Reported community use is usually 250 to 500 micrograms injected under the skin daily, but this has not been well tested for safety or effectiveness.
What this means for you: KPV has promising early research, but human evidence is still weak. It is not yet proven enough to buy or use for inflammation.
early evidenceKPV is a small peptide with an unusually clean mechanism. Alpha-MSH is a 13-amino-acid hormone that binds melanocortin receptors and modulates pigmentation, appetite, and inflammation. The KPV tripeptide, corresponding to residues 11-13 of the parent, retains the anti-inflammatory activity through independent NF-kB pathway suppression, without the melanocortin receptor binding that drives pigmentation and appetite effects.
Preclinical evidence is consistent across multiple models. In dextran sulfate sodium (DSS) colitis models in mice, oral KPV at low milligram-per-kilogram doses reduced weight loss, colonic shortening, and inflammatory cytokines. In contact dermatitis models, topical KPV reduced ear thickness and neutrophil infiltration. Mechanistically, KPV directly inhibits IL-1beta signaling and reduces NF-kB nuclear translocation in macrophages and epithelial cells.
Human trial evidence is thin. Small open-label studies have been reported in ulcerative colitis and inflammatory bowel disease, with modest signals of improvement in endoscopic and symptomatic scores. No large placebo-controlled trial has been completed.
The regulatory landscape changed in July 2026. The FDA Pharmacy Compounding Advisory Committee (PCAC) voted 12 to 1 to recommend KPV for inclusion on the 503A bulk drug substances list, which would allow compounding pharmacies to legally prepare KPV for individual patients under a prescription. This vote went against the recommendation of FDA's own review scientists, who cited insufficient safety data. The vote is non-binding; the FDA now enters a formal rule-making process that will take 12 to 24 months, and the final decision can go either way. PCAC also voted for BPC-157, MOTS-c, TB-500, Epitalon, and Semax in the same session.
Inside the biohacker community, KPV is used at 250 to 500 mcg subcutaneous once daily, or as a topical formulation for skin inflammation, in 4 to 8 week cycles. Reported side effect profile is quiet.
Our position: KPV sits at Tier 4. Solid preclinical mechanism, small unblinded human signals, and now a favorable (though non-binding) regulatory vote. The next 12 to 24 months will clarify whether it enters the legal compounding channel in the US.
KPV has zero human trials of any kind, only mouse colitis models and cultured cell data, despite an FDA advisory panel voting to recommend compounding access in July 2026.
Verified 2026-08-06. We update this section as PCAC decisions, ClinicalTrials.gov entries, and new peer-reviewed studies land.
FDA / PCAC (July 2026)
Reviewed July 23-24, 2026. The PCAC voted 8-6-1 to recommend KPV for the 503A Bulks List, against FDA staff's own briefing document recommending against all seven reviewed peptides (https://www.fda.gov/media/193343/download). The vote is advisory and non-binding (https://validusbio.com/learn/pcac-2026-peptide-vote-results/); STAT News reported this as part of a broader panel win for compounding-pharmacy access to unproven peptides (https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/).
US status
Not FDA approved for any indication; not currently on the 503A Bulks List. Removed from FDA's Category 2 list in April 2026 after its nomination was withdrawn, an administrative technicality, not an approval or access expansion.
EU status
Not authorised for human use in EU as of 2026.
Best-supported claim
The foundational KPV research is a 2007-2008 Gastroenterology study showing the tripeptide is taken up via the PepT1 transporter in human intestinal epithelial cell lines and reduces inflammation in two chemically induced mouse colitis models (DSS and TNBS) (https://pmc.ncbi.nlm.nih.gov/articles/PMC2431115/). This is a legitimate mechanistic finding, but it is in vitro human cells and live mice, not a human clinical outcome. No follow-up human trial has been registered or published in the nearly two decades since.
Not supported by the evidence base
KPV is marketed heavily for inflammatory bowel disease, acne, and general skin inflammation, and is a core ingredient in the unregulated four-peptide "KLOW" stack (with GHK-Cu, and others) sold with no combination safety data (https://newtropin.com/blog/kpv-gi-dermatological-inflammation-research). Vendor pages cite the 2007 mouse-colitis paper as if it were clinical proof of human IBD benefit. There has never been a human trial of KPV for any condition, and combination protocols like KLOW carry known copper-toxicity risk from the GHK-Cu component with no studied interaction profile.
Typical usage
200-500 mcg subcutaneous or oral/topical (for skin indications) daily, in research-chemical and compounding protocols; no clinical dosing standard exists because no human trial has ever been conducted.
Safety
No human safety data exist at all; every finding is derived from mouse colitis models and human cell cultures (https://pmc.ncbi.nlm.nih.gov/articles/PMC2431115/). KPV is frequently sold as part of the KLOW combination protocol with GHK-Cu, which has documented copper-toxicity risk when doses are combined without monitoring; there are no safety studies on the combination itself (https://newtropin.com/blog/kpv-gi-dermatological-inflammation-research). Anyone with Wilson's disease or a copper-metabolism disorder should avoid KPV-containing stacks. Pregnant people and anyone immunocompromised should avoid it given the total absence of human immunogenicity data.
Interactions worth flagging
- No formal human drug-interaction studies exist
- Combined with GHK-Cu in the unstudied "KLOW" protocol; risk of copper accumulation
- Unknown interaction profile with immunosuppressants given its anti-inflammatory mechanism
Three recent studies to know
-
PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation
KPV is transported via PepT1 into human intestinal epithelial cells and reduces inflammation in two mouse colitis models; no human participants were involved.
Read study → -
What the FDA's July 2026 PCAC Peptide Review Decided
PCAC voted 8-6-1 to recommend KPV for the 503A Bulks List against FDA staff's own negative position; non-binding.
Read study → -
In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides
FDA advisory panel recommended allowing compounding pharmacies to manufacture KPV along with BPC-157, TB-500, and MOTS-c; recommendation is non-binding.
Read study →
Further reading
Curated external sources for a deeper dive. External links open in a new tab.